Bajaj Healthcare Ltd
Bajaj Healthcare Ltd (BAJAJHCARE) last traded at ₹320, a market capitalisation of ₹1,076 crore, on a P/E of 19.1. Over the past 52 weeks the stock has ranged between ₹272 and ₹516. Bajaj Healthcare Ltd last reported results for the quarter ended Jun 2026, with sales of ₹166 crore and net profit of ₹14 crore. Figures are as of 25 Aug 2026 and are not real time.
Bajaj Healthcare Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Bajaj Healthcare Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹166 cr, up 11.4% from ₹149 cr a year earlier. Net profit was ₹14 cr, up 16.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 133 | 123 | 154 | 149 | 148 | 161 | 153 | 166 |
| Expenses | 109 | 101 | 143 | 124 | 121 | 131 | 130 | 137 |
| Operating profit | 25 | 22 | 12 | 25 | 27 | 31 | 23 | 29 |
| OPM % | 18% | 18% | 8% | 16% | 18% | 19% | 15% | 17% |
| Other income | 4 | -1 | 13 | 1 | 0 | 1 | -34 | 1 |
| Interest | 8 | 6 | 6 | 5 | 6 | 6 | 6 | 6 |
| Depreciation | 7 | 7 | 8 | 6 | 7 | 7 | 8 | 7 |
| Profit before tax | 14 | 8 | 11 | 14 | 15 | 19 | -24 | 16 |
| Tax % | 30% | -39% | 1% | 17% | 24% | 17% | -6% | 16% |
| Net profit | 9 | 12 | 11 | 12 | 11 | 16 | -23 | 14 |
| EPS (₹) | 3.00 | 3.71 | 3.54 | 3.75 | 3.52 | 4.96 | -6.79 | 4.07 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bajaj Healthcare Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 657 | 680 | 646 | 473 | 543 | 611 | 628 |
| Operating profit | 136 | 119 | 112 | 76 | 83 | 105 | 109 |
| OPM % | 21% | 17% | 17% | 16% | 15% | 17% | 17% |
| Net profit | 83 | 71 | 43 | -84 | 40 | 16 | 18 |
| EPS (₹) | 30.11 | 25.87 | 15.59 | -30.36 | 12.51 | 4.68 | 5.76 |
TTM is the trailing twelve months to the most recent quarter.
Bajaj Healthcare Ltd growth and returns
- 10 Years
- 11%
- 5 Years
- -1%
- 3 Years
- -2%
- TTM
- 12%
- 10 Years
- 19%
- 5 Years
- -11%
- 3 Years
- 3%
- TTM
- 20%
- 10 Years
- 18%
- 5 Years
- -6%
- 3 Years
- 1%
- 1 Year
- -27%
- 10 Years
- 12%
- 5 Years
- 9%
- 3 Years
- 4%
- Last Year
- 9%
Bajaj Healthcare Ltd shareholding pattern
Promoters held 58.59% at Jun 2026, down from 59.19% at Jun 2025. FIIs 2.19% and DIIs 1.92%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 59.19% | 59.19% | 59.19% | 59.19% | 59.19% | 59.19% | 58.29% | 58.59% |
| FIIs | 1.07% | 1.01% | 1.05% | 1.09% | 1.12% | 1.18% | 1.98% | 2.19% |
| DIIs | 1.97% | 2.36% | 2.52% | 3.16% | 2.99% | 2.96% | 2.91% | 1.92% |
| Public | 37.77% | 37.45% | 37.25% | 36.56% | 36.70% | 36.67% | 36.82% | 37.30% |
| No. of shareholders | 31,995 | 32,672 | 35,710 | 35,980 | 38,576 | 37,953 | 38,158 | 41,310 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Bajaj Healthcare Ltd corporate filings
- Intimation of allotment of equity shares pursuant to exercise of ESOPsCompany Updatelow impact
Cruxal's analysis: Bajaj Healthcare Ltd has formally intimated the allotment of equity shares following the…
Read the full analysis - The Company has received the approval from DCGI to manufacture and market Cenobamate API and TabletsCompany Updatemedium impact
Cruxal's analysis: Bajaj Healthcare Ltd has secured regulatory approval from the Drug Controller General of…
Read the full analysis - Revision in Credit RatingCompany Updatehigh impact
Cruxal's analysis: Bajaj Healthcare Limited has received a credit rating upgrade for its bank loan…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Bajaj Healthcare Ltd
Cruxal reads every Bajaj Healthcare Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.